PD60-09 ROLE AND VALUE OF SECOND OPINION REVIEWS IN DNA METHYLATION POSITIVE EPIGENETIC ASSAYS IN NEGATIVE HISTOPATHOLGICAL PROSTATE BIOPSIES

You have accessJournal of UrologyProstate Cancer: Detection & Screening VII (PD60)1 Apr 2019PD60-09 ROLE AND VALUE OF SECOND OPINION REVIEWS IN DNA METHYLATION POSITIVE EPIGENETIC ASSAYS IN NEGATIVE HISTOPATHOLGICAL PROSTATE BIOPSIES John Lam*, David Finley, Stephen Poon, William Sohn, Yu Wang, Philip Kim, Stephen Williams, Eugene Rhee, Ronald Loo, Gary Gochman, and Jeffrey Shiffer John Lam*John Lam* More articles by this author , David FinleyDavid Finley More articles by this author , Stephen PoonStephen Poon More articles by this author , William SohnWilliam Sohn More articles by this author , Yu WangYu Wang More articles by this author , Philip KimPhilip Kim More articles by this author , Stephen WilliamsStephen Williams More articles by this author , Eugene RheeEugene Rhee More articles by this author , Ronald LooRonald Loo More articles by this author , Gary GochmanGary Gochman More articles by this author , and Jeffrey ShifferJeffrey Shiffer More articles by this author View All Author Informationhttps://doi.org/10.1097/01.JU.0000557269.89460.3eAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVES: Genomic markers have been increasingly utilized to assist in the early detection of prostate cancer and an epigenetic assay has been able to identify men who may forego an unnecessary repeat biopsy. This study looked at the value of a second opinion review in positive epigenetic assays in negative histopathological prostate biopsies. METHODS: We evaluated the archived, cancer negative prostate biopsy core tissue samples of 49 subjects from an integrated health care system in Southern California. Biopsy cores were epigenetically profiled for GSTP1, APC and RASSF1 relative to the ACTB reference gene using quantitative methylation specific polymerase chain reaction in patients with rising PSA or increasing clinical suspicion. Predetermined analytical marker cutoffs were used to determine assay performance. DNA methylation positive biopsy cores underwent second opinion review by a pathologist. RESULTS: The epigenetic assay was performed in 49 cases of negative histopathological prostate biopsy cores, and found to be negative in 32 (65%) cases and positive in 17 (35%) cases. ASAP was present in 3 (6%) cases and HGPIN was present in 2 (4%) cases. Four (24%) of 17 positive cases that underwent second opinion review revealed the presence of prostate cancer. All prostate cancer diagnosed were Gleason score 6. In addition, there were 4 (24%) cases of ASAP and 4 (24%) cases of HGPIN diagnosed. CONCLUSIONS: Second opinion review of a positive epigenetic assay in histopathological negative prostate biopsies resulted in a proportion of cases having the diagnosis of prostate cancer. These results suggest that epigenetic assays can be used to assist with prostate cancer diagnosis and may circumvent need for repeat prostate biopsy or have implications in surveillance strategies. Source of Funding: None. Pasadena, CA© 2019 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 201Issue Supplement 4April 2019Page: e1099-e1100 Advertisement Copyright & Permissions© 2019 by American Urological Association Education and Research, Inc.MetricsAuthor Information John Lam* More articles by this author David Finley More articles by this author Stephen Poon More articles by this author William Sohn More articles by this author Yu Wang More articles by this author Philip Kim More articles by this author Stephen Williams More articles by this author Eugene Rhee More articles by this author Ronald Loo More articles by this author Gary Gochman More articles by this author Jeffrey Shiffer More articles by this author Expand All Advertisement PDF downloadLoading ...